免疫球蛋白联合激素冲击疗法治疗重症肌无力的临床效果

Clinical Effect of Immunoglobulin Combined with Hormone Shock Therapy in the Treatment of Myasthenia Gravis

目的:探究免疫球蛋白联合激素冲击疗法治疗重症肌无力的效果。方法:将2021年1月—2024年1月韩城市人民医院收治的100例重症肌无力患者纳入研究,使用信封法随机分为联合组和激素组,各50例。激素组接受常规激素冲击疗法治疗,联合组在激素组基础上接受免疫球蛋白治疗。对比两组治疗有效率、重症肌无力日常生活量表(MG-ADL)评分、重症肌无力肌群耐力评分量表(MG-MES)评分、T淋巴细胞亚群水平及药物不良反应发生情况。结果:联合组治疗有效率高于激素组(P=0.037);治疗后,两组MG-ADL、MG-MES评分均降低,联合组低于激素组(P<0.05);治疗后,两组CD4^(+)、CD4^(+)/CD8^(+)水平升高,CD8^(+)水平降低,联合组优于激素组(P<0.05);两组不良反应发生率无统计学差异(P>0.05)。结论:免疫球蛋白联合激素冲击疗法对重症肌无力患者疗效显著,可有效帮助患者恢复肌力,改善免疫功能,旦未增加不良反应发生风险。

Objective:To explore the effect of immunoglobulin combined with hormone shock therapy on myasthenia gravis.Methods:One hundred patients with myasthenia gravis admitted to Hancheng People's Hospital from January 2021 to January 2024 were included in the study and randomly divided into combination group and hormone group by envelope method,with fifty cases in each group.The hormone group received conventional hormone shock therapy,and the combination group received immunoglobulin therapy on the basis of the hormone group.The treatment effectiveness,myasthenia gravis daily living scale(MG-ADL)score,myasthenia gravis muscle endurance scale(MG-MES)score,T lymphocyte subsets level and the occurrence of adverse drug reactions were compared between the two groups.Results:The effective rate of combination group was higher than that of hormone group(P=0.037);after treatment,MG-ADL and MG-MES scores were decreased in both groups,and those in combination group were lower than those in hormone group(P<0.05);after treatment,the levels of CD4^(+),CD4^(+)/CD8^(+)increased and CD8^(+)decreased in both groups,and the combination group was better than the hormone group(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Immunoglobulin combined with hormone shock therapy is effective in patients with myasthenia gravis,and can effectively help patients recover muscle strength and improve immune function without increasing the risk of adverse reactions.